During the past decade, Pharmacovigilance Department conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pharmacovigilance Department" are "Antidiuretic Hormone, Inappropriate Secretion" (1 trials), "Bipolar Disorder I" (1 trials) and "Migraine Disorders" (1 trials). Many other conditions were trialed in "Pharmacovigilance Department" in a lesser frequency.

Most popular intervention types in "Pharmacovigilance Department" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)" (1 trials), "Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution" (1 trials) and "Tolvaptan (SAMSCA)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pharmacovigilance Department" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Pharmacovigilance Department". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Pharmacovigilance Department, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pharmacovigilance Department, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".